Dimethyl Sulfoxide
Apexbio Technology LLC Vardenafil 224785-90-4 10mM (in 1mL DMSO)
Vardenafil (CAS 224785-90-4) is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5) It inhibits PDE5 enzyme activity with an IC50 of approximately 0 7 nM in vitro Compared with other PDE isoforms (PDE1-4 and PDE6) vardenafil demonstrates superior selectivity toward PDE5 though moderate inhibition of PDE6 (IC50 11 nM) is observed Vardenafil enhances cGMP accumulation in human corpus cavernosum and significantly potentiates nitric oxide (SNP)- acetylcholine- and electrical field stimulation-induced relaxation in human trabecular smooth muscle Its vasodilatory effects render it suitable for research in erectile function and related vascular physiology
Apexbio Technology LLC Chlorocresol 10mM (in 1mL DMSO)
B1696 is a small molecule compound utilized in biomedical research primarily due to its modulatory effects on specific cellular signaling pathways Although the explicit molecular target is currently unpublished available evidence indicates that B1696 influences cellular processes implicated in inflammation immune response and cell proliferation Researchers employ this compound to investigate disease mechanisms and signaling networks within in vitro or ex vivo experimental systems contributing valuable information on therapeutic intervention strategies and drug development efforts
Apexbio Technology LLC AZD6482 1173900-33-8 10mM (in 1mL DMSO)
AZD6482 (CAS 1173900-33-8) is a selective ATP-competitive inhibitor of phosphoinositide 3-kinase beta (PI3K ) It exhibits inhibitory potency with IC50 values of 0 69 nM for PI3K compared to 13 6 nM for PI3K 47 8 nM for PI3K and 136 nM for PI3K In vitro AZD6482 reduces insulin-induced glucose uptake in human adipocytes (IC50 of 4 4 M) Preclinical studies in dogs indicate anti-thrombotic activity without elevating bleeding risks Clinical evaluation showed good tolerability in human volunteers with modest effects on insulin sensitivity parameters AZD6482 serves as a valuable tool to investigate PI3K function in platelet biology and metabolic regulation
Apexbio Technology LLC Eptifibatide 188627-80-7 10mM (in 1mL DMSO)
Eptifibatide is a cyclic heptapeptide belonging to the glycoprotein IIb/IIIa inhibitor category functioning as an antagonist of platelet adhesion by reversibly binding to the platelet glycoprotein IIb/IIIa receptor This receptor located on platelet surfaces mediates platelet aggregation through binding fibrinogen and von Willebrand factor processes essential in thrombus formation By blocking the GP IIb/IIIa receptor binding site Eptifibatide inhibits fibrinogen-dependent platelet cross-linking reducing platelet aggregation In biomedical research Eptifibatide serves as a pharmacological tool to investigate platelet function thrombosis mechanisms and related cardiovascular diseases in preclinical and clinical models
Apexbio Technology LLC Batimastat (BB-94)(Synonyms: BB-94, Batimastat, MMP inhibitor BB-94), 10mM (in 1mL DMSO), CAS: 130370-60-4.
Batimastat (BB-94 CAS 130370-60-4) is a synthetic small-molecule inhibitor targeting matrix metalloproteinases (MMPs) Structurally a polypeptide-like analogue of collagen substrates batimastat contains a peptidic backbone and a hydroxamate moiety that binds the catalytic zinc atom of MMPs It inhibits several MMP subtypes markedly including MMP-1 MMP-2 MMP-3 MMP-7 and MMP-9 with reported IC50 values of 3 4 20 6 and 4 nM respectively In preclinical studies batimastat demonstrates inhibitory effects on tumor growth and angiogenesis across various tumor models including ovarian and colon carcinoma xenografts making it relevant for cancer research and therapeutic development
Apexbio Technology LLC KPT-185 1333151-73-7 10mM (in 1mL DMSO)
KPT-185 (CAS 1333151-73-7) is an irreversible selective inhibitor of chromosome region maintenance 1 (CRM1) a nuclear export receptor essential for nuclear-cytoplasmic transport KPT-185 binds covalently at Cys528 of CRM1 thereby inhibiting CRM1-mediated nuclear export of tumor suppressor proteins Studies demonstrate that KPT-185 impairs proliferation and colony formation in acute myeloid leukemia (AML) cell lines exhibiting IC50 values ranging from 100 500 nM inducing G1 cell cycle arrest apoptosis and differentiation of AML blasts Additionally KPT-185 reduces growth and promotes apoptosis in pancreatic cancer models (Colo-357 HPAC BxPC-3) highlighting its potential in cancer research
Apexbio Technology LLC AM1241(Synonyms: AM-1241, CB2 receptor agonist AM1241, Cannabinoid receptor CB2 agonist AM1241, AM 1241), 10mM (in 1mL DMSO), CAS: 444912-48-5.
AM1241 (CAS number 444912-48-5) is a selective agonist of the cannabinoid receptor type 2 (CB2) a G protein-coupled receptor encoded by the CNR2 gene CB2 receptors modulate inflammation and neuropathic pain pathways outside the central nervous system In vitro studies suggest stereoisomer-dependent activities specifically the S-enantiomer demonstrates higher functional potency toward human and rodent CB2 receptors compared to the R-enantiomer In animal models AM1241 administration reduces neuropathic pain phenotypes including hyperalgesia and allodynia and shows potential for delaying disease progression in an ALS (amyotrophic lateral sclerosis) mouse model Currently AM1241 remains a valuable investigational tool in preclinical pain and neurodegeneration research
Apexbio Technology LLC Dacomitinib (PF299804, PF299) 1110813-31-4 10mM (in 1mL DMSO)
Dacomitinib (PF299804 CAS 1110813-31-4) is an irreversible pan-HER small-molecule inhibitor that targets the epidermal growth factor receptor (EGFR/ErbB-1) ERBB2 (HER2) and ERBB4 (HER4) It acts by covalently binding EGFR family tyrosine kinases inhibiting downstream signaling through phospho-HER family proteins AKT and ERK Dacomitinib shows activity in vitro inducing G0/G1 cell cycle arrest and apoptosis and suppresses proliferation in trastuzumab- or lapatinib-resistant HER2-amplified breast cancer cell lines In vivo studies demonstrate antitumor effects in EGFR-mutant (e g T790M) gefitinib-resistant lung cancer xenografts making it relevant for non-small cell lung cancer research
Apexbio Technology LLC Etonogestrel(Synonyms: 3-Ketodesogestrel, Implanon, Nexplanon, ORG-3236, 11-Methylenelevonorgestrel), 10mM (in 1mL DMSO), CAS: 54048-10-1.
Etonogestrel (CAS 54048-10-1) is a synthetic steroidal molecule derived as the biologically active metabolite of the progestin desogestrel Structurally it belongs to the 19-nortestosterone class and acts primarily through potent binding and agonist activity at progesterone receptors Through this receptor binding it modulates various physiological processes including ovulation suppression cervical mucus viscosity enhancement and endometrial alteration Etonogestrel serves as a widely researched hormonal contraceptive with applications in reproductive biology studies endocrinological research and pharmaceutical development
Apexbio Technology LLC MK-8245 1030612-90-8 10mM (in 1mL DMSO)
MK-8245 (CAS 1030612-90-8) is a potent liver-selective small molecule inhibitor of stearoyl-CoA desaturase (SCD) SCD1 catalyzes fatty acid desaturation and represents a target for treating type II diabetes obesity dyslipidemia and other metabolic disorders MK-8245 demonstrates strong inhibitory activity against rat mouse and human SCD1 with an IC50 of approximately 1 nM and displays liver-specific tissue distribution mediated by organic anion transporting polypeptides (OATPs) Animal studies revealed MK-8245 reduces blood glucose levels and hepatic triglycerides dose-dependently supporting its application in metabolic disease research
Apexbio Technology LLC PF-477736 952021-60-2 10mM (in 1mL DMSO)
PF-477736 is an ATP-competitive small-molecule inhibitor of checkpoint kinase 1 (Chk1) It selectively inhibits Chk1 kinase activity demonstrating nanomolar inhibitory potency in kinase assays and exhibits lower affinity toward related kinases such as CDK1 and Chk2 In vitro studies utilizing human cancer cell lines show PF-477736 disrupts Chk1-dependent G2-phase cell-cycle arrest induced by DNA-damaging agents preferentially targeting tumor cells with compromised p53 function while minimizing cytotoxicity to normal cells PF-477736 is widely utilized experimentally to study DNA damage response mechanisms potential chemosensitizing effects and therapeutic implications for cancers harboring p53 mutations
Apexbio Technology LLC ASC-J9(Synonyms: Dimethylcurcumin, GO-Y025, AR degrader enhancer ASC-J9), 10mM (in 1mL DMSO), CAS: 52328-98-0.
ASC-J9 (CAS 52328-98-0) is a small-molecule degrader targeting androgen receptor (AR) By promoting degradation of full-length AR and splice variants such as AR3/fAR ASC-J9 inhibits androgen receptor signaling pathways involved in castration-resistant prostate cancer (CRPC) progression and metastatic behavior ASC-J9 interferes with AR-dependent transcriptional modulation and AR-independent signaling pathways notably inhibiting STAT3 phosphorylation and CCL2 chemokine secretion thus reducing macrophage infiltration and prostate cancer invasiveness Research indicates ASC-J9 may represent an alternative therapeutic strategy for CRPC treatment and metastasis prevention
Cayman Chemical L-MethIonIn SulfoxIde 1g
A sulfoxide-modified methionine; increases weight gain in weanling mice in the diet at 6.3, 12.6, and 18.9 mmol/g; levels are decreased in patients with vitiligo
Apexbio Technology LLC Erlotinib Hydrochloride 183319-69-9 10mM (in 1mL DMSO)
Erlotinib hydrochloride (CAS 183319-69-9) is a small molecule inhibitor targeting the epidermal growth factor receptor (EGFR/HER-1) specifically blocking its tyrosine kinase activity By competitively inhibiting EGFR phosphorylation (IC50 2 nM) Erlotinib hydrochloride disrupts downstream signaling pathways involved in tumor cell proliferation apoptosis resistance migration and angiogenesis In vitro studies indicate this inhibitor induces G0/G1 cell cycle arrest and promotes apoptosis in cancer cell lines such as pancreatic (Bxpc-3 PANC-1) and hepatocellular carcinoma cells Erlotinib hydrochloride is widely studied in oncology research particularly in non-small cell lung cancer (NSCLC) and pancreatic cancer models